<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089775</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-2000-CL-101</org_study_id>
    <nct_id>NCT03089775</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis</brief_title>
  <acronym>BBI</acronym>
  <official_title>A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brickell Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brickell Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two cohort study (Cohort A and B) is being conducted to assess the safety and efficacy
      of BBI-2000 for the prevention (Cohort A) and treatment (Cohort B) of delayed type
      hypersensitivity reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This two cohort (Cohort A and B) single-center, randomized, controlled study is being
      conducted to evaluate the safety and efficacy of BBI-2000 for the prevention (Cohort A) and
      treatment (Cohort B) of delayed type hypersensitivity (DTH) reactions.

      Subjects in Cohort A will initially receive either pre-treatment with BBI-2000 or vehicle, on
      an area on the back. Diphencyprone (DPCP) will then be administered, via Finn chamber, to the
      same area on the back. The treated area will then be assessed to determine if BBI-2000 was
      effective in preventing a contact hypersensitivity reaction.

      Cohort B will first be sensitized with DPCP as in Cohort A. Indicated regions of the back
      will then be challenged to illicit a DTH reaction. Following the challenge, indicated regions
      on the subject's back will be treated with either (A) BBI-2000, (B) vehicle, (C) no topical
      application or (D) clobetasol propionate. The efficacy of BBI-2000 will be evaluated by
      monitoring response of the area of contact hypersensitivity reaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">May 24, 2017</completion_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events in each study group</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of the number and severity of adverse event between study groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs, physical examinations, ECG, blood analysis, urine analysis</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in vital signs, physical examinations, ECG, blood and urine analyses between study groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Size of contact hypersensitivity reaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean diameter (mm) of the contact hypersensitivity reaction induced by DPCP for subjects randomized to BBI-2000 (5%) as compared with vehicle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermal thickness</measure>
    <time_frame>4 weeks</time_frame>
    <description>Contact hypersensitivity reactions will be quantified using a high-frequency 20-Megahertz (MHz) ultrasound scanner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter (mm) of the contact hypersensitivity area</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean diameter (mm) of the contact hypersensitivity reaction induced by DPCP for areas randomized to BBI-2000, as compared with vehicle, no treatment, and clobetasol propionate over time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>BBI-2000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple treatments</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-2000</intervention_name>
    <description>Experimental</description>
    <arm_group_label>BBI-2000</arm_group_label>
    <arm_group_label>Multiple treatments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Comparator</description>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_label>Multiple treatments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiple treatments</intervention_name>
    <description>BBI-2000, Vehicle, Clobetasol Propionate, No treatment</description>
    <arm_group_label>Multiple treatments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals aged 18 to 65 years inclusive at the time of consent, and either female of
             non-reproductive potential or male.

          -  Subjects must be healthy, normal volunteers per physical exam, laboratory and EKG
             assessments

        Exclusion Criteria:

          -  History of contact dermatitis to medical adhesive bandages or glue.

          -  Medical history of dermatographism.

          -  Any medical condition causing immunosuppression.

          -  Prior treatment or therapies or history of sensitivity to any of the study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence A Romel, MS</last_name>
    <role>Study Director</role>
    <affiliation>Brickell Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact</keyword>
  <keyword>Treatment</keyword>
  <keyword>Prevention</keyword>
  <keyword>BBI-2000</keyword>
  <keyword>Dermatitis</keyword>
  <keyword>Allergic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

